Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine for SLC7A11-positive advanced pancreatic ductal adenocarcinoma
ACTRN12621001347853Phase 2Recruiting
- Sponsor
- Omico
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminosalicylic acid + sulphasalazine in pancreatic adenocarcinoma (PDAC), sponsored by Omico. Primary endpoint: Progression-free survival rate at 6 months. Started Jun 2023; status: recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12621001347853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001347853.